Efficacy and safety of tenecteplase in ST elevation myocardial infarction patients from the Elaxim Indian Registry.
OBJECTIVE
to study the efficacy and safety of indigenously developed tenecteplase injection in the management of Indian STEMI patients in clinical practice.


METHODS
post-licensure, observational, prescription event monitoring study.


RESULTS
2100 patients received weight-adjusted tenecteplase injection. More than 90% patients received aspirin, clopidogrel, and enoxaparin/heparin. Clinically successful thrombolysis was reported in 86.71%, in-hospital mortality was 3.48%. The adverse events recorded were comparable with previously published data. Any bleeding (excluding intra-cranial hemorrhage) was seen in 4.62% patients which was reported in 0.90% patients of which 47.34% patients had also received GpIIb/IIIa inhibitors.


CONCLUSIONS
This study confirms the efficacy and safety of indigenous tenecteplase in Indian STEMI patients.
Iyengar
S S
SS
Department of Cardiology, St. John's Medical College & Hospital, Bangalore, Karnataka, India. cardioresearch@gmail.com
Nair
Tiny
T
Sathyamurthy
I
I
Hiremath
J S
JS
Jadhav
U
U
Kumbla
D
D
Jain
R K
RK
Srinivasan
M
M
Sahoo
P K
PK
Chawla
Kamaldeep
K
Katiyal
V K
VK
D000368:Aged; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007194:India; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D012042:Registries; D000077785:Tenecteplase; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D000077785:Tenecteplase